First patient dosed in landmark trial for GAD treatment

First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex

Moderna and Merck reported Phase 3 trial success for intismeran autogene, marking the first personalized mRNA cancer vaccine to meet primary endpoints in high-risk melanoma.

Moderna shares surged 131% after its Phase 3 INTerpath-001 trial of intismeran autogene with Keytruda met primary melanoma endpoints, triggering $4.8B in short-seller losses.

Company secures first commercial product with data for active and chronic TED